Biogen

Angelman syndrome
Angelman syndrome Pipeline: Unmet needs call for a robust pipeline

The necessity of a robust Angelman syndrome pipeline is indispensable at the current moment because of a shortage of any approved therapy option available in the market. The Angelman Syndrome c...


pharma-biotech-news-updates-for-biogen-pfizer-viiv-calliditas
Pfizer’s COVID-19 Vaccine; Calliditas’ NefIgArd trial; ViiV’s HIV Prevention Tr...

Pfizer's COVID-19 vaccine heralded as the showstopper with over 90% effectiveness  Based on the interim data from the Phase III COVID-19 vaccine trial results, the pharma titan, Pfizer, an...


Latest pharma happenings for Roche and Secura Bio
FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulce...

Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy  The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of Genentech, a Roche c...


recent-pharma-news
AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes

AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised U...


pharma news
Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s...

Eli Lilly has announced to buy a biopharmaceutical company, Dermira, for a whopping sum of USD 1.1 Billion in an all-cash transaction. Through the acquisition, Eli Lilly is planning to expand ...


Alzheimer's disease
Biogen seeks the FDA approval to revive its Alzheimer’s drug Aducanumab

Not a long time ago this year, Biogen announced the halting of Phase III clinical trials, EMERGE and ENAGE, of its most looked upon drug aducanumab under simulations for the treatment of Alzheimer...


Meet the World’s most expensive drug: Zolgensma

The U.S. FDA recently approved the much talked about Novartis’s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy (SMA).  SMA is a neuromuscular disorder that w...


Spinal Muscular Atrophy
Can Spinal Muscular Atrophy be treated by Protease Inhibitors?

Spinal muscular atrophy is a genetic disorder characterised by weakness and wasting (atrophy) of skeletal muscles, used for movement. Loss of specialised nerve cells, called motor neurons which co...


Alzheimer’s drug fails! Is it time to move on?

Alzheimer’s is one of the diseases which are irreversible and untreatable. With causes still unknown adds to the further conundrum.  But for more than two decades now Scientists from everywhe...


mRNA
Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Sl...

Biogen to buy Nightstar for USD 800 Million Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar. The deal will let Bi...


Editor's Pick
Can denovoSkin Be A Lifesaver for Burn Victims?

Burn is a global public health problem, causing more than 180,000 deaths per year acros...

NexoBrid and its Awaiting US Approval

A Burn takes place when the skin comes into contact with a heat source. Burns can occur...

New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Do...

Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...

Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.